M&A Deal Summary

Charles River Laboratories International Acquires SAMDI Tech

On January 30, 2023, Charles River Laboratories International acquired life science company SAMDI Tech for 50M USD

Acquisition Highlights
  • This is Charles River Laboratories International’s 28th transaction in the Life Science sector.
  • This is Charles River Laboratories International’s 12th largest (disclosed) transaction.
  • This is Charles River Laboratories International’s 20th transaction in the United States.
  • This is Charles River Laboratories International’s 1st transaction in Illinois.

M&A Deal Summary
Date 2023-01-30
Target SAMDI Tech
Sector Life Science
Buyer(s) Charles River Laboratories International
Deal Type Add-on Acquisition
Deal Value 50M USD

Target

SAMDI Tech

Chicago, Illinois, United States
SAMDI Tech is a provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. SAMDI Tech offers a proprietary mass spectrometry (MS) technology for high-throughput analysis of biochemical activities and affinity selection MS (SAMDI ASMS) for identifying binding interactions. SAMDI Tech was founded in 2011 and is based in Chicago, Illinois.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Charles River Laboratories International

Wilmington, Massachusetts, United States
Category Company
Founded 1947
Sector Life Science
Employees20,400
Revenue 4.1B USD (2023)
DESCRIPTION

Charles River Laboratories International is a provider of essential products and contract services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Charles River Laboratories International was incorporated in 1947 and is based in Wilmington, Massachusetts.

DEAL STATS #
Overall 31 of 31
Sector (Life Science) 28 of 28
Type (Add-on Acquisition) 26 of 26
State (Illinois) 1 of 1
Country (United States) 20 of 20
Year (2023) 1 of 1
Size (of disclosed) 12 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-05 AVS Bio

Norwich, Connecticut, United States

AVS Bio is a provider of specific pathogen free eggs and adjacent laboratory products and services that support the development and manufacture of vaccines, therapeutics, and other biologics used for human and animal health. AVS Bio was founded in 1961 and is based in Norwich, Connecticut.

Sell -
Mergr

Product

Company

Legal